Get the Stockscreener App
502.50
0.24%
1.35
Vertex Pharmaceuticals Inc stock is traded at $502.50, with a volume of 581.77K.
It is up +0.24% in the last 24 hours and up +5.84% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$501.15
Open:
$501.45
24h Volume:
581.77K
Relative Volume:
0.40
Market Cap:
$127.64B
Revenue:
$11.02B
Net Income/Loss:
$-535.60M
P/E Ratio:
-228.41
EPS:
-2.2
Net Cash Flow:
$-978.00M
1W Performance:
+1.18%
1M Performance:
+5.84%
6M Performance:
+0.50%
1Y Performance:
+25.25%
1-Day Range:
$498.02
$505.61
1-Week Range:
$490.85
$510.77
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
502.51 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.87 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
655.55 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.95 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.97 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Abandons AAV as Gene Therapy Space Weathers Difficulties - BioSpace
3 No-Brainer Stocks to Buy in May - The Motley Fool
Gilead and Vertex Pharma named among biotech’s tariff safe havens - MSN
How Will Vertex Pharmaceuticals Stock React To Its Upcoming Earnings? - Nasdaq
Vertex Pharmaceuticals (VRTX) Earnings Preview: What to Expect - GuruFocus
Vertex discontinues AAV research for gene therapies - Fierce Biotech
As Journavx rollout begins, Vertex kicks off unbranded pain campaign with NFL alum Alex Smith - Fierce Pharma
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global and CME Group - MSN
What Analyst Projections for Key Metrics Reveal About Vertex (VRTX) Q1 Earnings - Nasdaq
Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
European regulators recommend new drugs from Vertex, Amgen and Jazz - Endpoints News
, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
US Health Secretary Reportedly Says 35 States to Join Pilot Program for Sickle Cell Disease Gene Therapies - marketscreener.com
EMA Backs Vertex Pharmaceuticals' (VRTX) Alyftrek for Cystic Fib - GuruFocus
Vertex’s Alyftrek For CF Among Six Orphans On Track For Pan-EU Approval - insights.citeline.com
Vertex Pharmaceuticals Stock (VRTX) Trending as Q1 Earnings Approach - TipRanks
Vertex Pharmaceuticals (VRTX) Advances But Underperforms Market: Key Facts - Yahoo Finance
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday - MSN
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect - Nasdaq
Vertex Pharmaceuticals’ Q1 2025 Earnings: What To Expect - Barchart.com
Eli Lilly, Vertex, AbbVie and More Pharma Stocks to Own as Tariffs Loom - MSN
Eli Lilly, Vertex, AbbVie, and More Pharma Stocks to Own as Tariffs Loom - Barron's
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price T - GuruFocus
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts - Benzinga
Vertex Pharmaceuticals (VRTX) Gains Favor with Increased Price Target | VRTX Stock News - GuruFocus
ToolGen sues Vertex over alleged unlicensed use of CRISPR tech in gene therapy - koreabiomed.com
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Faces UK Patent Lawsuit Over Groundbreaking CASGEVY Therapy - simplywall.st
ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom - Longview News-Journal
Lobbying Update: $1,600,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Reshma Kewalramani Among TIME’s 100 Most Influential People Of 2025 - IndiaWest
Reshma Kewalramani among 2025 Time 100 most influential people - The American Bazaar
Peering Into Vertex Pharmaceuticals's Recent Short Interest - Benzinga
Reshma Kewalramani named among Time magazine's 100 most influential people - Firstpost
Vertex’s Attempt to Redefine AKS Falls Short: Key Insights for Pharma Manufacturers - ArentFox Schiff
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $617 From $615, Maintains Buy Rating - marketscreener.com
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis - BioSpace
Vertex Pharmaceuticals (VRTX) Celebrated for Groundbreaking CF R - GuruFocus
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? - AOL.com
Lobbying Update: $20,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):